Hepatitis B and C
Chronic viral hepatitis infections usually caused by hepatitis type C (HCV) or less frequently hepatitis type B (HBV) are deadly diseases that attack the liver. The World Health Organization (WHO) estimates that globally 170 million people are chronically infected with HCV and that 3 to 4 million are newly infected each year. HBV, which is 50 to 100 times more infectious than HIV, has infected about 2 billion people worldwide, and 350 million live with chronic infection.

Lack of testing is in part a result of the inability to inexpensively collect blood samples and transport them to the testing laboratory. Current methods of collecting and shipping include dried blood spots (DBS) and frozen plasma. However, these methods suffer from low sample volume and expensive shipping regulations, respectively. These factors inhibit the number of tests that are performed because it is too expensive to ship the necessary volume of specimen from many tests.



The ViveBio Solution
ViveBio is working with collaborators who utilize its solutions to simplify transport of specimens from patient to laboratory. ViveST has been tested as an inexpensive shipping method for both HCV and HBV specimens with subsequent viral load and genotype testing. The ViveST workflow is well suited for busy high-tech laboratories or resource limited low-tech laboratories.

Select Publications
Comparative Effectiveness of Dried Plasma HBV Viral Load Testing in Three Different Viral Load Commercial Platforms Using ViveST for Sample Collection. Journal of Clinical Microbiology, Jan 2012, p. 145-147

Dried-Plasma Transport Using a Novel Matrix Collection System for Human Immunodefiency Virus and Hepatitis C Virus Virologic Testing Journal of Clinical Microbiology, May 2009, p. 1491-1496

Comparison of Hepatitis Quantitative and Qualitative Methods Using ViveST Sample Transportation Matrix vs Frozen Plasma. 26th Clinical Virology Symposium; April 25-28, 2010; Daytona Beach, FL, USA